Search

Your search keyword '"David J. Kuter"' showing total 325 results

Search Constraints

Start Over You searched for: Author "David J. Kuter" Remove constraint Author: "David J. Kuter"
325 results on '"David J. Kuter"'

Search Results

1. Rilzabrutinib placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study

2. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies

3. Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features

4. Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report

5. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia

6. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

7. American Society of Hematology 2019 guidelines for immune thrombocytopenia

8. Updated international consensus report on the investigation and management of primary immune thrombocytopenia

9. Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance

10. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

11. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies

12. The role of romiplostim for pediatric patients with immune thrombocytopenia

13. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia

16. Pure White Cell Aplasia and Necrotizing Myositis

17. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease

20. Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

21. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia

22. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia

24. Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

25. Novel therapies for immune thrombocytopenia

26. Biomarkers associated with coronary high-risk plaques

28. Quantification of local zinc and tungsten deposits in bone with LA-ICP-MS using novel hydroxyapatite-collagen calibration standards

30. Tungsten accumulates in the intervertebral disc and vertebrae stimulating disc degeneration and upregulating markers of inflammation and pain

32. Facile synthesis of a C4-symmetrical inherently chiral calix[4]arene

35. Scoring system to facilitate diagnosis of Gaucher disease

36. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia

37. An evaluation of avatrombopag for the treatment of thrombocytopenia

38. Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 ( <scp>COVID</scp> ‐19)

39. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies

40. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study

41. Sutimlimab improves quality of life in patients with cold agglutinin disease : results of patient-reported outcomes from the CARDINAL study

42. Lessons learned using real-world data to emulate randomized trials-a case study of treatment effectiveness for newly diagnosed immune thrombocytopenia

43. EIGHTEEN-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION

44. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag

45. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

46. Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

47. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia

48. Hydrating the Bispropionate Notch in Malaria Pigment: A New Structural Motif in the Iron(III)(deuteroporphyrin) Dimer

49. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( <scp>ITP</scp> ) for up to 1 year and in those with chronic <scp>ITP</scp> for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies

50. Exacerbation of immune thrombocytopenia following COVID-19 vaccination

Catalog

Books, media, physical & digital resources